DongYeop Lee - HLB Pharmaceutical Managing Director
| 047920 Stock | KRW 24,100 400.00 1.69% |
Insider
DongYeop Lee is Managing Director of HLB Pharmaceutical Co
| Age | 60 |
| Phone | 82 411 1500 |
| Web | http://www.c-tri.co.kr |
HLB Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0219 % which means that it generated a profit of $0.0219 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (11.3917) %, meaning that it generated substantial loss on money invested by shareholders. HLB Pharmaceutical's management efficiency ratios could be used to measure how well HLB Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 11 records | INSIDER Age | ||
| MunHee Park | Kolon Life Science | N/A | |
| SangJun Lee | Kolon Life Science | 62 | |
| MyungKwan Suh | Kolon Life Science | 61 | |
| JaeGwan Lee | Aminologics CoLtd | 64 | |
| WooSok Lee | Kolon Life Science | 66 | |
| SangWoo Lee | Kolon Life Science | 59 | |
| TaeHwan Kim | Kolon Life Science | 73 | |
| KyungII Kim | Aminologics CoLtd | 65 | |
| WonSup Kim | Aminologics CoLtd | 64 | |
| SangHu Park | Kolon Life Science | 61 | |
| HunYeol Yun | Aminologics CoLtd | 61 | |
Management Performance
| Return On Equity | -11.39 | |||
| Return On Asset | 0.0219 |
HLB Pharmaceutical Leadership Team
Elected by the shareholders, the HLB Pharmaceutical's board of directors comprises two types of representatives: HLB Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HLB. The board's role is to monitor HLB Pharmaceutical's management team and ensure that shareholders' interests are well served. HLB Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HLB Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| JongBin Kim, Managing Director | ||
| Dong Lee, Assistant Managing Director | ||
| Jeong Yoo, Assistant Managing Director | ||
| Jae Noh, Internal Auditor | ||
| Hae Park, Chief Executive Officer, Director | ||
| DongYeop Lee, Managing Director | ||
| Jeong Yoon, Director | ||
| WanJoo Kim, Chief Director | ||
| Yong Cho, Managing Director | ||
| JungBok Yoo, Managing Director | ||
| Dae Son, Director | ||
| Jong Kim, Managing Director | ||
| Yeong Jeon, Director |
HLB Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is HLB Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -11.39 | |||
| Return On Asset | 0.0219 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 216.14 B | |||
| Shares Outstanding | 13.85 M | |||
| Shares Owned By Insiders | 25.75 % | |||
| Shares Owned By Institutions | 0.13 % | |||
| Price To Sales | 5.60 X | |||
| Revenue | 62.85 B |
Pair Trading with HLB Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HLB Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HLB Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving together with HLB Stock
Moving against HLB Stock
The ability to find closely correlated positions to HLB Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HLB Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HLB Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HLB Pharmaceutical Co to buy it.
The correlation of HLB Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HLB Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HLB Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HLB Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in HLB Stock
HLB Pharmaceutical financial ratios help investors to determine whether HLB Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLB with respect to the benefits of owning HLB Pharmaceutical security.